DE3586020D1 - Verfahren zur schaffung genetisch manipulierter tiere. - Google Patents

Verfahren zur schaffung genetisch manipulierter tiere.

Info

Publication number
DE3586020D1
DE3586020D1 DE8585304490T DE3586020T DE3586020D1 DE 3586020 D1 DE3586020 D1 DE 3586020D1 DE 8585304490 T DE8585304490 T DE 8585304490T DE 3586020 T DE3586020 T DE 3586020T DE 3586020 D1 DE3586020 D1 DE 3586020D1
Authority
DE
Germany
Prior art keywords
genetically manipulated
animal
creating genetically
manipulated animals
animals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8585304490T
Other languages
English (en)
Inventor
Philip Leder
Timothy A Stewart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24499353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3586020(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Harvard College filed Critical Harvard College
Application granted granted Critical
Publication of DE3586020D1 publication Critical patent/DE3586020D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Environmental Sciences (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
DE8585304490T 1984-06-22 1985-06-24 Verfahren zur schaffung genetisch manipulierter tiere. Expired - Lifetime DE3586020D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/623,774 US4736866A (en) 1984-06-22 1984-06-22 Transgenic non-human mammals

Publications (1)

Publication Number Publication Date
DE3586020D1 true DE3586020D1 (de) 1992-06-17

Family

ID=24499353

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585304490T Expired - Lifetime DE3586020D1 (de) 1984-06-22 1985-06-24 Verfahren zur schaffung genetisch manipulierter tiere.

Country Status (6)

Country Link
US (1) US4736866A (de)
EP (1) EP0169672B1 (de)
JP (1) JPS6181743A (de)
AT (1) ATE76102T1 (de)
CA (1) CA1341442C (de)
DE (1) DE3586020D1 (de)

Families Citing this family (654)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US7767449B1 (en) 1981-12-24 2010-08-03 Health Research Incorporated Methods using modified vaccinia virus
US5174993A (en) * 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
FR2596414B1 (fr) * 1986-03-28 1989-10-06 Pasteur Institut Hybridomes obtenus a partir de lymphocytes d'animaux transgeniques portant un gene exprimant une proteine donnee et procede de preparation d'une telle proteine a partir de tels hybridomes
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
ES2171401T3 (es) * 1986-05-20 2002-09-16 Gen Hospital Corp Metodos para estudios farmacocineticos de la expresion de insulina con un mamifero transgenico no-humano.
US5366894A (en) * 1986-06-30 1994-11-22 Pharmaceutical Proteins Limited Peptide production
US5470560A (en) * 1987-01-20 1995-11-28 Genentech, Inc. Method for evaluating immunogenicity
EP0832981A1 (de) * 1987-02-17 1998-04-01 Pharming B.V. DNA-Sequenzen die Proteine zwecks effizienter Abscheidung zur Milchdrüse leiten
ATE132266T1 (de) * 1987-05-01 1996-01-15 Stratagene Inc Mutagenesetest durch verwendung von nicht menschlichen lebewesen, die test-dns-sequenzen enthalten
US5928637A (en) * 1987-06-16 1999-07-27 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods of inducing multidrug resistance using human MDR1 cDNA
US5075229A (en) * 1987-06-16 1991-12-24 Ohio University Edison Animal Biotechnology Center Dietary and hormonal regulation of expression of exogenous genes in transgenic animals under control of the promoter of the gene for phosphoenolpyruvate carboxykinase
US5851819A (en) * 1987-06-16 1998-12-22 National Institutes Of Health Vectors carrying MDR1 cDNA which confer multidrug resistance on transduced cells
JPH03500482A (ja) * 1987-06-16 1991-02-07 オハイオ ユニバーシティ ホスホエノールピルベート　カルボキシキナーゼに係る遺伝子のプロモーターの制御下における、遺伝子導入動物の外来遺伝子の発現の食餌およびホルモンによる調節
FR2637613B1 (fr) * 1987-06-19 1991-09-27 Transgene Sa Procede de preparation de lignees cellulaires stables pour la production de proteines determinees, a partir d'animaux transgeniques; lignees cellulaires tumorales et proteines obtenues
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5851991A (en) * 1987-08-31 1998-12-22 The Regents Of The University Of California Therapeutic use of the retinoblastoma susceptibility gene product
US7105156B1 (en) 1987-09-17 2006-09-12 The Regents Of The University Of California Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells
EP0390857A4 (en) * 1987-12-15 1991-04-17 The Trustees Of Princeton University Transgenic testing systems for mutagens and carcinogens
US20030032178A1 (en) * 1988-08-04 2003-02-13 Williams Robert Lindsay In vitro propagation of embryonic stem cells
US5221778A (en) * 1988-08-24 1993-06-22 Yale University Multiplex gene regulation
US6436701B1 (en) 1988-09-21 2002-08-20 Babraham Institute Derivation of pluripotential embryonic cell lines from ungulate species
GB2223755A (en) * 1988-09-21 1990-04-18 Cambridge Animal Biotech Tissue modification
EP0451157A4 (en) * 1988-10-21 1992-01-02 Us Health Transgenic animals for testing multidrug resistance
CA2001815C (en) * 1988-10-31 2002-09-03 Wen-Hwa Lee Products and methods for controlling the suppression of the neoplastic phenotype
US6277591B1 (en) 1988-11-18 2001-08-21 Oregon Health Science University Dopamine receptors and genes
AU620477B2 (en) * 1988-11-30 1992-02-20 Upjohn Company, The Transgenic mice for the analysis of hair growth
CA2006011A1 (en) * 1988-12-21 1990-06-21 Cecilia Lo Transgenic organisms and cells and methods of producing transgenic organisms and cells
US5215904A (en) * 1989-01-27 1993-06-01 Wisconsin Alumni Research Foundation Method for producing a recombinant mammal in vivo
US5175383A (en) * 1989-02-17 1992-12-29 President And Fellows Of Harvard College Animal model for benign prostatic disease
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
DK198089D0 (da) * 1989-04-24 1989-04-24 Danske Spritfabrikker Dna-materialer og anvendelse deraf
US5498832A (en) * 1989-04-24 1996-03-12 A/S De Danske Spritfabrikker Potato α-amylase genes
WO1990015869A1 (en) * 1989-06-19 1990-12-27 Embryogen Corporation Transgenic skin-testing systems
US6218596B1 (en) * 1989-06-30 2001-04-17 The United States Of America As Represented By The Department Of Health And Human Services Enhancement of musculature in non-human mammals expressing c-ski
US5174986A (en) * 1989-07-05 1992-12-29 Genpharm International, Inc. Method for determining oncogenic potential of a chemical compound
CA2035464A1 (en) * 1989-07-05 1991-01-06 Anton J. M. Berns Method for determining oncogenic potential of a chemical compound
US5580722A (en) * 1989-07-18 1996-12-03 Oncogene Science, Inc. Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
US6203976B1 (en) 1989-07-18 2001-03-20 Osi Pharmaceuticals, Inc. Methods of preparing compositions comprising chemicals capable of transcriptional modulation
KR100194562B1 (ko) * 1989-07-18 1999-06-15 로버트 반 노스트랜드 전사단계에서의 유전자 발현의 조절방법 및 유전자 발현 조절 인자로서 작용할수 있는 화학물의 발견방법
US5665543A (en) * 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
US5776502A (en) 1989-07-18 1998-07-07 Oncogene Science, Inc. Methods of transcriptionally modulating gene expression
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US6689610B1 (en) * 1989-08-22 2004-02-10 University Of Utah Research Foundation Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and vectors for making same
CA2066614A1 (en) * 1989-09-15 1991-03-16 Cha-Mer Wei Transgenic animal model for viral infections
AU6882791A (en) * 1989-11-22 1991-06-13 Children's Hospital Of Los Angeles Bcr/abl transgenic animals as models for philadelphia chromosome positive chronic myelogenous and acute lymphoblastic leukemia
US5633076A (en) * 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5225546A (en) * 1990-01-24 1993-07-06 President And Fellows Of Harvard College Diagnosis of hereditary retinal degenerative disease
US5498521A (en) * 1990-01-24 1996-03-12 President And Fellows Of Harvard College Diagnosis of hereditary retinal degenerative diseases
US5262529A (en) * 1990-01-24 1993-11-16 President And Fellows Of Harvard College Diagnosis of hereditary retinal degenerative diseases
GB9003791D0 (en) * 1990-02-20 1990-04-18 Ludwig Inst Cancer Res Transgenic animals,cell lines therefrom,and their use
WO1991013979A1 (en) * 1990-03-05 1991-09-19 President And Fellows Of Harvard College Transgenic mouse overexpressing il-4 and method of use
WO1991015116A1 (en) * 1990-03-30 1991-10-17 Amrad Corporation Limited Doubly transgenic animals
EP0608210A1 (de) * 1990-04-05 1994-08-03 Stratagene Mutagenesetest unter verwendung von nichtmenschlichen lebewesen, die test dna-sequenzen enthalten
US5244656A (en) * 1990-05-04 1993-09-14 Wisconsin Alumni Research Foundation Antigen specific plasmacytomas and antibodies derived therefrom
US5614396A (en) * 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
GB9017020D0 (en) * 1990-08-02 1990-09-19 Cancer Res Campaign Tech Nucleic acid sequences having unusual properties and uses thereof
WO1992006104A1 (en) * 1990-09-28 1992-04-16 The Dana-Farber Cancer Institute Adipocyte-specific dna sequences and use for the production of transgenic animals exhibiting altered fat metabolism
US5489742A (en) * 1990-10-23 1996-02-06 Board Of Regents, The University Of Texas System Transgenic rats and animal models of inflammatory disease
AU9120191A (en) * 1990-12-03 1992-06-25 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Enhancement of musculature in animals
JPH06503967A (ja) * 1991-01-04 1994-05-12 ベイラー・カレッジ・オブ・メディシン 腫瘍感受性非ヒト動物
US5569824A (en) * 1991-01-04 1996-10-29 Baylor College Of Medicine Transgenic mice containing a disrupted p53 gene
WO1992013091A1 (en) * 1991-01-18 1992-08-06 Oncogene Science, Inc. Methods of transcriptionally modulating expression of oncogenes and tumor suppressor genes
US5866759A (en) * 1991-02-20 1999-02-02 Ludwig Institute For Cancer Research Transgenic mice expressing TSSV40 large T antigen
WO1992017602A1 (en) * 1991-04-05 1992-10-15 The General Hospital Corporation Office Of Technology Affairs Parathyroid hormone receptor and dna encoding same
US7150974B1 (en) 1991-04-05 2006-12-19 The General Hospital Corporation Parathyroid hormone receptor binding method
US5261686A (en) * 1992-04-06 1993-11-16 Buckler Clive E Semi-recumbent
US7132260B2 (en) * 1991-04-05 2006-11-07 The General Hospital Corporation DNA encoding parathyroid hormone receptor
WO1992020790A1 (en) * 1991-05-15 1992-11-26 L'institut De Recherches Cliniques De Montreal Transgenic non-human animal carrying a non-infectious hiv genome
US6268211B1 (en) 1991-08-20 2001-07-31 L'institut De Recherches Cliniques De Montreal Non-infectious HIV transgene
WO1992022333A1 (en) * 1991-06-12 1992-12-23 Thomas Jefferson University Transgenic mice expressing human collagen gene
DE4126968A1 (de) * 1991-08-14 1993-02-18 Detlev Prof Dr Med Ganten Transgene ratten, die in ihrem genom mindestens ein menschliches gen enthalten, das an der blutdruckregulation beteiligt ist
AU2765992A (en) 1991-10-03 1993-05-03 Indiana University Foundation Method for screening for alzheimer's disease
AU2861892A (en) * 1991-10-04 1993-05-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Astrocyte-specific transcription of human genes
US5614393A (en) * 1991-10-10 1997-03-25 Rhone-Poulenc Agrochimie Production of γ-linolenic acid by a Δ6-desaturase
US20070130654A1 (en) * 1991-10-10 2007-06-07 Thomas Terry L Production of gamma linolenic acid by a delta6-desaturase
PH31293A (en) * 1991-10-10 1998-07-06 Rhone Poulenc Agrochimie Production of y-linolenic acid by a delta6-desaturage.
US20090077692A1 (en) * 1991-10-10 2009-03-19 Thomas Terry L Production of gamma linolenic acid by a delta6-desaturase
US6683232B1 (en) * 1991-10-10 2004-01-27 Rhone-Poulenc Agrochimie Production of γ linolenic acid by a Δ6-desaturase
DE69233477T2 (de) * 1991-11-14 2006-02-16 Prionics Ag Transgene nicht-menschliche tiere ohne prionprotein
DK8892D0 (da) 1992-01-23 1992-01-23 Symbicom Ab Humant proteingen
US5859307A (en) * 1992-02-04 1999-01-12 Massachusetts Institute Of Technology Mutant RAG-1 deficient animals having no mature B and T lymphocytes
WO1993015769A1 (en) * 1992-02-14 1993-08-19 Stratagene Mutagenesis testing using transgenic non-human animals carrying test dna sequences
US5914265A (en) * 1992-04-30 1999-06-22 Baylor College Of Medicine Keratin K1 expression vectors and methods of use
CA2134675A1 (en) * 1992-04-30 1993-11-11 Dennis R. Roop Development of a vector to target gene expression to the epidermis of transcenic animals
ATE365209T1 (de) * 1992-05-14 2007-07-15 Baylor College Medicine Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie
US6416998B1 (en) 1992-09-02 2002-07-09 Baylor College Of Medicine Plasmid encoding a modified steroid hormone
EP0648265A4 (de) * 1992-06-18 1996-12-04 Genpharm Int Methoden zur herstellung von nicht-humanen transgenen tieren die ein artifizielles hefe chromosom enthalten.
US6610493B1 (en) * 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US5602307A (en) * 1992-08-12 1997-02-11 Baylor College Of Medicine Non-human animal having predefined allele of a cellular adhesion gene
US5714146A (en) * 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
US6264915B1 (en) 1992-09-13 2001-07-24 The President And Fellows Of Harvard College Process for detecting potential carcinogens
US5833945A (en) * 1992-09-30 1998-11-10 Sakuma; Moto Animal model of pathological behavior
CA2110946A1 (en) 1992-12-09 1994-06-10 Elazar Rabbani Induction of immunocompatibility by nucleic acid
US5912121A (en) * 1992-12-11 1999-06-15 Bringham And Women's Hospital Methods for detecting mutations associated with hypertrophic cardiomyopathy
US20020127548A1 (en) * 1992-12-11 2002-09-12 Christine Siedman Methods for detecting mutations associated with hypertrophic cardiomyopathy
US5650278A (en) * 1992-12-22 1997-07-22 Children's Hospital Of Philadelphia Compositions and diagnostic kits for identifying alveolar rhabdomyosarcoma
US5981175A (en) * 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
US5489743A (en) * 1993-01-19 1996-02-06 Amgen Inc. Transgenic animal models for thrombocytopenia
CA2159195A1 (en) * 1993-03-26 1994-10-13 Darwin J. Prockop Use of a col 1a1 mini-gene construct to inhibit collagen synthesis
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
US5718883A (en) * 1993-04-14 1998-02-17 The United States Of America As Represented By The Secretary Of The Navy Transgenic animal model for autoimmune diseases
US5523226A (en) * 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
US5789651A (en) * 1993-05-21 1998-08-04 Martin Marietta Energy Systems, Inc. Isolation and characterization of Agouti: a diabetes/obesity related gene
US6310034B1 (en) 1993-05-21 2001-10-30 Ut-Battelle, Llc Agouti polypeptide compositions
US5547868A (en) * 1993-06-09 1996-08-20 Regents Of The University Of California Cholesterol disposal fusion enzymes
US5731411A (en) * 1993-07-12 1998-03-24 The United States Of America As Represented By The Department Of Health And Human Services Promotion of homologous DNA pairing by RecA-derived peptides
US5824837A (en) * 1993-07-22 1998-10-20 Merck & Co., Inc. Expression of human interleukin-1β in a transgenic animal
US5650550A (en) * 1993-10-01 1997-07-22 The United States Of America As Represented By The Department Of Health And Human Services Mutant mice having a deficit of functional estrogen receptors
US5602309A (en) * 1993-10-04 1997-02-11 University Of Kentucky Research Foundation Transgenic mice which overexpress nerve growth factor
JPH09507746A (ja) 1993-10-27 1997-08-12 アテナ ニューロサイエンシズ，インコーポレイティド Ｓｗｅｄｉｓｈ変異を有するＡＰＰ対立遺伝子を含有するトランスジェニック動物
AU8102694A (en) * 1993-11-17 1995-06-06 Id Biomedical Corporation Cycling probe cleavage detection of nucleic acid sequences
US5466465A (en) * 1993-12-30 1995-11-14 Harrogate Holdings, Limited Transdermal drug delivery system
US6025183A (en) * 1994-02-28 2000-02-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Transgenic animal assay system for anti-cholinesterase substances
US5932780A (en) * 1994-02-28 1999-08-03 Yissum Research Development Company Of Hebrew University Of Jerusalem Transgenic non-human animal assay system for anti-cholinesterase substances
US5858774A (en) * 1994-05-12 1999-01-12 The Research Foundation Of State University Of New York Antisense DNA constructs for expression of hybrid MRNAs driven by inducible, tissue-specific promoters
AU2635295A (en) * 1994-06-13 1996-01-05 Henry Ford Health System A novel neuronal-neonatal gene: neuronatin
US5601820A (en) * 1994-07-07 1997-02-11 Children's Hospital Of Philadelphia Compositions and methods of making and using human full length TRK-B
US20030152909A1 (en) * 1994-11-16 2003-08-14 Mitrani Eduardo N. In vitro micro-organs, and uses related thereto
US5714170A (en) 1994-11-16 1998-02-03 Thomas Jefferson University Method of inducing resistance to tumor growth
US5859308A (en) * 1994-12-29 1999-01-12 University Of Medicine And Denistry Of New Jersey Transgenic animals and related aspects
US6046037A (en) * 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
AU722668B2 (en) 1994-12-30 2000-08-10 King's College London Methods for producing immunoglobulins containing protection proteins in plants and their use
US6808709B1 (en) 1994-12-30 2004-10-26 The Regents Of The University Of California Immunoglobulins containing protection proteins and their use
US5702948A (en) * 1995-02-02 1997-12-30 The Trustees Of The University Of Pennsylvania Saccular collagen and compositions and methods for making and using the same
US5675063A (en) * 1995-02-28 1997-10-07 Loyola University Of Chicago Immortalized rabbit hybridoma fusion partner
US5814300A (en) * 1995-03-03 1998-09-29 Cephalon, Inc. Gene-targeted non-human mammals deficient in the SOD-1 gene
US5674748A (en) * 1995-03-14 1997-10-07 Thomas Jefferson University Human cyclin-dependent kinase-like proteins and methods of using the same
US5714378A (en) * 1995-03-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Navy Pseudomonas chlororaphis microorganism polyurethane degrading enzyme obtained therefrom and method of using enzyme
US5858661A (en) 1995-05-16 1999-01-12 Ramot-University Authority For Applied Research And Industrial Development Ataxia-telangiectasia gene and its genomic organization
US5728807A (en) * 1995-05-16 1998-03-17 Ramot-University Authority For Applied Research And Industrial Development, Ltd. Mutated proteins associated with ataxia-telangiectasia
US5777093A (en) * 1995-05-16 1998-07-07 Ramot-University Authority For Applied Research & Industrial Development Ltd. cDNAs associated with ataxia-telangiectasia
US5672500A (en) * 1995-05-18 1997-09-30 Thomas Jefferson University Mch2, an apoptotic cysteine protease, and compositions for making and methods of using the same
US6187991B1 (en) 1995-05-23 2001-02-13 Pfizer Inc Transgenic animal models for type II diabetes mellitus
US5876949A (en) * 1995-05-31 1999-03-02 The Trustees Of The University Of Pennsylvania Antibodies specific for fragile X related proteins and method of using the same
US5691187A (en) * 1995-06-07 1997-11-25 Thomas Jefferson University Anti-fungal agents and methods of identifying and using the same
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
CA2223484A1 (en) * 1995-06-07 1996-12-19 Thomas Jefferson University Anti-fungal agents and methods of identifying and using the same
US5817783A (en) * 1995-06-22 1998-10-06 Thomas Jefferson University DR-nm23 and compositions, methods of making and methods of using the same
US6010694A (en) * 1995-07-27 2000-01-04 Thomas Jefferson University Fibrillin 1 gene comprising duplication mutation and compositions and kits using the same
WO1997005484A1 (en) * 1995-07-28 1997-02-13 Beth Israel Deaconess Medical Center, Inc. A method of and test kit for mutagenesis testing
WO1997007827A1 (en) * 1995-08-22 1997-03-06 Thomas Jefferson University Gab1, A Grb2 BINDING PROTEIN, AND COMPOSITIONS FOR MAKING AND METHODS OF USING THE SAME
US6248555B1 (en) 1995-08-31 2001-06-19 The General Hospital Corporation Genetic alterations related to familial alzheimer's disease
CA2227306A1 (en) * 1995-09-01 1997-03-27 Ramot-University Authority For Applied Research And Industrial Developme Nt Ltd. Manipulation and detection of protein phosphatase 2c - pp2c.alpha. - expression in tumor cells for cancer therapy, prevention and detection
EP0876480A4 (de) * 1995-10-20 1999-10-20 Ludwig Inst Cancer Res Tiere mit gezielter gendeletion
US5861498A (en) * 1995-11-01 1999-01-19 Thomas Jefferson University Nucleotides encoding immunophilin FKBP46 and fragments thereof
EP0861267A4 (de) * 1995-11-14 2000-02-02 Univ Jefferson Induktion und resistenz gegen tumorwachstum mittels loeslichem igf-1
US5859311A (en) * 1995-11-27 1999-01-12 University Of Kentucky Research Foundation Transgenic mice which overexpress neurotrophin-3 (NT-3) and methods of use
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US6998116B1 (en) * 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US5907079A (en) * 1996-01-18 1999-05-25 Amgen Canada Inc. MSH2 disrupted mice develop lymphomas
US6060587A (en) 1996-01-29 2000-05-09 The Trustees Of The University Of Pennsylvania Cellular receptor for HIV-1 VPR essential for G2/M phase transition of the cell cycle
US5834279A (en) * 1996-03-07 1998-11-10 Trustees Of The University Of Pennsylvania Methods of identifying compounds that inhibit DNA synthesis in mycobacterium tuberculosis and compositions, reagents and kits for performing the same
US6140309A (en) * 1996-03-12 2000-10-31 University Of South Florida Vasoactive effects and free radical generation by β-amyloid peptides
US6333447B1 (en) 1996-03-29 2001-12-25 The General Hospital Corporation Transgenic model of heart failure
EP1500702A1 (de) * 1996-04-01 2005-01-26 Genentech, Inc. APO-2LI and APO-3 Apoptosis Polypeptides aus der TNFR1 Familie
US20020165157A1 (en) * 1996-04-01 2002-11-07 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
US5919901A (en) * 1996-04-08 1999-07-06 Bayer Corporation Neuropeptide Y receptor Y5 and nucleic acid sequences
US5965392A (en) 1996-04-08 1999-10-12 Bayer Corporation Neuropeptide Y receptor Y5 and nucleic acid sequences
US20030033617A1 (en) * 1996-04-10 2003-02-13 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20020160970A1 (en) * 1996-04-10 2002-10-31 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6077697A (en) 1996-04-10 2000-06-20 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
GB9607953D0 (en) 1996-04-17 1996-06-19 Univ Liverpool Transgenic rat
CA2254082C (en) * 1996-05-03 2012-09-11 Thomas Jefferson University Metastatic colorectal cancer vaccine
US5824838A (en) * 1996-05-09 1998-10-20 Cedars-Sinai Medical Center Transgenic mouse model for pituitary disorders associated with LIF overexpression and/or GH underexpression, and its use for testing therapeutic drugs for the conditions
JP2000513230A (ja) 1996-07-01 2000-10-10 エイ． ライト，ジム ハウスキーピング遺伝子の非翻訳領域由来のオリゴヌクレオチドおよび細胞増殖を調節するためのその使用方法
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US6353151B1 (en) 1996-09-26 2002-03-05 University Technology Corporation Transgenic model for heart failure
US5990281A (en) * 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
US5898094A (en) * 1996-10-21 1999-04-27 University Of South Florida Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
JP2001504690A (ja) * 1996-10-29 2001-04-10 バレンティス・インコーポレーテッド 遺伝子治療用の改変ステロイドホルモン及びそれらの使用法
US5858778A (en) * 1996-12-27 1999-01-12 Thomas Jefferson University SF caspase-1 and compositions for making and methods of using the same
CA2284778A1 (en) 1997-03-26 1998-10-01 Jerome J. Strauss Endometriosis mouse model
US20020102706A1 (en) * 1997-06-18 2002-08-01 Genentech, Inc. Apo-2DcR
US6399358B1 (en) 1997-03-31 2002-06-04 Thomas Jefferson University Human gene encoding human chondroitin 6-sulfotransferase
WO1999010484A1 (en) * 1997-08-26 1999-03-04 Genentech, Inc. Rtd receptor
ES2285768T5 (es) 1997-04-16 2011-12-22 Millennium Pharmaceuticals, Inc. Proteínas crsp (proteínas segregadas ricas en cisteína), moléculas de ácido nucleico que codifican para las mismas y uso.
AU7023798A (en) 1997-04-30 1998-11-24 De Novo Enzyme Corporation Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
US20100152426A1 (en) * 1997-05-15 2010-06-17 Ashkenazi Avi J Apo-2 receptor fusion proteins
DK0981618T4 (da) * 1997-05-15 2011-11-21 Genentech Inc Anti-Apo-2-antistof
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US6037461A (en) * 1997-05-20 2000-03-14 Thomas Jefferson University FADD-like anti-apoptotic molecules, methods of using the same, and compositions for and methods of making the same
US6541036B1 (en) 1997-05-29 2003-04-01 Thomas Jefferson University Treatment of tumors with oligonucleotides directed to insulin-like growth factor-I receptors (IGF-IR)
US6426411B1 (en) 1997-05-30 2002-07-30 Dana-Farber Cancer Institute PGC-1, a novel brown fat pparγ coactivator
EP1003856A1 (de) 1997-06-05 2000-05-31 Board of Regents, The University of Texas System Apaf-1, menschluches ced-4 homolog, ein aktivator von caspase-3
AU740227B2 (en) * 1997-06-18 2001-11-01 Genentech Inc. Apo-2DcR
US6087166A (en) 1997-07-03 2000-07-11 Basf Aktiengesellschaft Transcriptional activators with graded transactivation potential
US6103466A (en) * 1997-07-14 2000-08-15 University Of Liege Double-muscling in mammals
PT2045322E (pt) * 1997-07-14 2015-10-16 Université de Liège Musculatura dupla em mamíferos
US20070067859A1 (en) * 1997-07-14 2007-03-22 Michel Georges Double-muscling in mammals
US7087420B1 (en) 1997-07-17 2006-08-08 Cambia Microbial β-glucuronidase genes, gene products and uses thereof
US6391547B1 (en) * 1997-09-09 2002-05-21 Center For The Application Of Molecular Biology To International Agriculture Microbial β-glucuronidase genes, gene products and uses thereof
US6498285B1 (en) 1997-08-06 2002-12-24 Alexion Pharmaceuticals, Inc. Methods for producing transgenic pigs by microinjecting a blastomere
US7135333B1 (en) 1997-08-07 2006-11-14 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US6120995A (en) * 1997-08-07 2000-09-19 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US20030104973A1 (en) * 1997-08-21 2003-06-05 Quark Biotech, Inc. Hypoxia-regulated genes
US7973156B2 (en) * 1997-08-21 2011-07-05 Quark Pharmaceuticals Inc. Hypoxia-regulated genes
AU9028298A (en) 1997-08-21 1999-03-08 Quark Biotech, Inc. Hypoxia-regulated genes
US20030175856A1 (en) * 1997-08-26 2003-09-18 Genetech, Inc. Rtd receptor
US5917124A (en) * 1997-09-12 1999-06-29 Washington University Transgenic mouse model of prostate cancer
EP1659131B1 (de) 1997-09-17 2009-11-04 Genentech, Inc. Polypeptide und dafür kodierende Nukleinsäure
ES2306480T3 (es) 1997-09-18 2008-11-01 Genentech, Inc. Polipeptido dcr3, un homologo de tnfr.
US20040231011A1 (en) * 2001-06-28 2004-11-18 Genentech, Inc. DcR3 polypeptide, a TNFR homolog
US6063359A (en) * 1997-09-26 2000-05-16 Washington University Method for determining oncogenic activity of a substance
EP1967587A1 (de) 1997-10-10 2008-09-10 Genentech, Inc. APO-3-Liganden
WO1999019466A2 (en) 1997-10-14 1999-04-22 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
ES2316173T3 (es) 1997-10-29 2009-04-01 Genentech, Inc. Genes inducibles por wnt-1.
EP2014770A3 (de) 1997-10-29 2009-02-18 Genentech, Inc. WNT-1-induziertes sekretiertes Polypeptid WISP-2
US7321023B2 (en) * 1997-11-07 2008-01-22 Incyte Corporation SP16 protein
ATE426036T1 (de) * 1997-11-14 2009-04-15 Cedars Sinai Medical Center Transfektion und transfer nicht humaner mannlicher keimzellen zur generierung transgener nicht humaner saugetiere
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
DE69840105D1 (de) 1997-11-21 2008-11-20 Genentech Inc Plättchen-spezifische antigene und deren pharmazeutische verwendung
US7687057B2 (en) 1998-01-09 2010-03-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem In vitro micro-organs, and uses related thereto
EP1045918B1 (de) 1998-01-12 2008-08-20 Pedro Jose G protein-verwandte kinasemutanten in der essentiellen hypertonie
DE69939732D1 (de) 1998-01-15 2008-11-27 Genentech Inc Apo-2 ligand
US6764830B1 (en) 1998-01-23 2004-07-20 The Regents Of The University Of California Thermomyces lanuginosus kinesin motor protein and methods of screening for modulators of kinesin proteins
US6727079B1 (en) 1998-02-25 2004-04-27 The United States Of America As Represented By The Department Of Health And Human Services cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
WO1999043697A1 (en) * 1998-02-25 1999-09-02 The Board Of Regents Of The University And Community College System Of Nevada On Behalf Of The University Of Nevada-Reno Manganese superoxide dismutase exon 3-deleted isoforms and nucleic acid molecules encoding the isoforms
EP2050762A3 (de) 1998-03-10 2009-07-08 Genentech, Inc. Neue Polypeptide und für diese kodierende Nukleinsäuren
IL138488A0 (en) 1998-03-17 2001-10-31 Genentech Inc Polypeptides homologous to vegf and bmp1
US6733991B1 (en) * 1998-05-08 2004-05-11 Osi Pharmaceuticals, Inc. AGS proteins and nucleic acid molecules and uses therefor
US6746852B1 (en) 1998-05-08 2004-06-08 Osi Pharmaceuticals, Inc. AGS proteins and nucleic acid molecules and uses thereof
EP3112468A1 (de) 1998-05-15 2017-01-04 Genentech, Inc. Il-17-homologe polypeptide und therapeutische verwendung davon
ES2292242T5 (es) 1998-05-15 2011-05-04 Genentech, Inc. Utilizaciones terapéuticas de polipéptidos homólogos de il-17.
US6548737B1 (en) 1998-05-15 2003-04-15 Barnes-Jewish Hospital Transgenic mice deficient in natural killer cells
EP1865061A3 (de) 1998-05-15 2007-12-19 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
CA2328604A1 (en) 1998-05-26 1999-12-02 Andrew Segal Compositions and methods of modulating an immune response to an antigen
US6753138B1 (en) * 1998-06-04 2004-06-22 Reprogen, Inc. Use of prothymosin in the diagnosis and treatment of endometriosis
PT1086138E (pt) * 1998-06-12 2010-01-04 Genentech Inc Anticorpos monoclonais, anticorpos de reacção cruzada e método para produzir os mesmos
US7291712B2 (en) 1998-06-25 2007-11-06 Genentech, Inc. Interleukin-8 homologous polypeptides and therapeutic uses thereof
US20070003545A9 (en) * 1999-06-02 2007-01-04 Eaton Dan L Interleukin-8 homologous polypeptides and therapeutic uses thereof
US6976904B2 (en) * 1998-07-09 2005-12-20 Li Family Holdings, Ltd. Chemical mechanical polishing slurry
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
CA2340456A1 (en) * 1998-08-18 2000-03-02 Yale University Lats knock-out animal models and their uses
US6448078B1 (en) 1998-10-09 2002-09-10 The Trustees Of The University Of Pennsylvania Cellular receptor for HIV-1 Vpr essential for G2/M phase transition of the cell cycle
US6495662B1 (en) * 1998-10-22 2002-12-17 The General Hospital Corporation Bioactive peptides and peptide derivatives of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP)
US7335737B2 (en) * 1998-10-28 2008-02-26 Baylor College Of Medicine Ovary-specific genes and proteins
US20060079674A1 (en) * 1998-10-28 2006-04-13 Baylor College Of Medicine Wyeth Contraceptive targets
EP1124840A4 (de) * 1998-10-28 2002-07-17 Baylor College Medicine Ovarspezifische gene und proteine
US20020042926A1 (en) * 1998-10-28 2002-04-11 Matzuk Martin M. Ovary-specific genes and proteins
US20030027998A1 (en) * 1998-10-30 2003-02-06 Holtzman Douglas A. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
US20060205034A1 (en) * 1998-10-30 2006-09-14 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
AU1409999A (en) * 1998-11-13 2000-06-05 University Of North Carolina At Chapel Hill, The Animal model for neurological disorders
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
MXPA01005275A (es) 1998-11-27 2003-06-06 Darwin Discovery Ltd Composiciones y metodos para aumentar la mineralizacion de huesos.
CA2450402A1 (en) 1998-12-22 2000-06-29 Genentech, Inc. Methods and compositions for inhibiting cancer cell growth comprising pro224
CA2354027A1 (en) 1998-12-23 2000-07-06 Genentech, Inc. Il-1 related polypeptides
US7057012B1 (en) * 1998-12-31 2006-06-06 The General Hospital Corporation PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
ATE403678T1 (de) * 1998-12-31 2008-08-15 Gen Hospital Corp Peptide, bestehend aus zwei funktionellen pth- domänen, die durch ein linkermolekül verknüpft sind, und derivate davon
EP1179000A4 (de) 1999-02-26 2005-10-12 Millennium Pharm Inc Ausscheidungsproteine und ihre verwendung
EP2357192A1 (de) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Menschliches alpha-Endokin und Verfahren zu seiner Verwendung
US6531125B1 (en) 1999-03-02 2003-03-11 Twinstrand Therapeutics Inc. Antiviral ricin-like proteins
US7105315B2 (en) * 1999-06-16 2006-09-12 Incyte Genomics, Inc. Transmembrane protein differentially expressed in cancer
US6911429B2 (en) * 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
EP1792989A1 (de) 1999-04-12 2007-06-06 Agensys, Inc. 13-Transmembrane Protein welches in Prostatakrebs exprimiert wird
EP1171595A1 (de) 1999-04-12 2002-01-16 Agensys, Inc. 13-transmembrane protein welches in prostatakrebs exprimiert wird
US20030131364A1 (en) * 1999-04-27 2003-07-10 Karen Duff Method for producing transgenic animal models with modulated phenotype and animals produced therefrom
AU779395B2 (en) * 1999-04-30 2005-01-20 Institut De Recherche Cliniques De Montreal (Ircm) Mutant human CD80 and compositions for and methods of making and using the same
US20040229779A1 (en) * 1999-05-14 2004-11-18 Ramesh Kekuda Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6974684B2 (en) * 2001-08-08 2005-12-13 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040023874A1 (en) * 2002-03-15 2004-02-05 Burgess Catherine E. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CA2305716A1 (en) 1999-05-28 2000-11-28 University Of Guelph Method for assay of wbpm
US9486429B2 (en) * 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
US6787318B1 (en) 1999-06-01 2004-09-07 Roskamp Research Institute, Llc Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US6346382B1 (en) 1999-06-01 2002-02-12 Vanderbilt University Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto
US20040067490A1 (en) * 2001-09-07 2004-04-08 Mei Zhong Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU5152700A (en) 1999-06-15 2001-01-02 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2004006831A2 (en) * 2002-07-12 2004-01-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method and device for inducing biological processes by micro-organs
CA2377541A1 (en) * 1999-06-25 2001-01-04 Eduardo N. Mitrani Method of inducing angiogenesis by micro-organs
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
EP1201759B1 (de) * 1999-07-14 2010-03-10 Transgenic Inc. "gen-fallen-vektor" und verfahren zum "einfangen" von genen mittels dieses vektors
US6610905B1 (en) 1999-07-21 2003-08-26 Schering Corporation Transgenic mouse model for Kaposi's sarcoma
US6639121B1 (en) * 1999-07-29 2003-10-28 Dana-Farber Cancer Institute, Inc. Inducible cancer model to study the molecular basis of host tumor cell interactions in vivo
US6602501B1 (en) 1999-08-12 2003-08-05 Agensys, Inc. C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
US6875582B1 (en) 1999-08-19 2005-04-05 Omniscience Pharmaceuticals, Inc. Methods and targets of antibiotic resistance
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
NZ523206A (en) * 1999-08-31 2004-12-24 Genentech Inc Antibodies that bind to tumor gene sequences
US6998232B1 (en) 1999-09-27 2006-02-14 Quark Biotech, Inc. Methods of diagnosing bladder cancer
US7022815B1 (en) 1999-09-29 2006-04-04 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (PTH)
ATE412670T1 (de) 1999-09-29 2008-11-15 Gen Hospital Corp Parathyroid hormon (pth) polypeptidderivate
WO2001023521A2 (en) * 1999-09-29 2001-04-05 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
EP2003202B1 (de) 1999-10-05 2011-09-14 Agensys, Inc. G Protein-gekoppelter in Prostatakrebs hochexprimierter Rezeptor und seine Verwendungen
US6855806B1 (en) * 1999-10-15 2005-02-15 Curagen Corporation Thymosin beta 10-like proteins and nucleic acids encoding same
US6893818B1 (en) * 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
ES2315244T3 (es) 1999-11-12 2009-04-01 Fibrogen, Inc. Gelatina recombinante en vacunas.
CA2496312A1 (en) 1999-12-01 2001-06-07 Kevin P. Baker Colon tumour marker pro4799 polypeptides and nucleic acids encoding the same
EP2210948A3 (de) 1999-12-10 2010-10-06 Life Technologies Corporation Verwendung von mehrfachen Rekombinationsstellen mit einzigartiger Spezifizität beim Rekombinationsklonen
DK1897945T3 (da) 1999-12-23 2012-05-07 Genentech Inc IL-17 homologe polypeptider og terapeutiske anvendelser deraf.
AU2288601A (en) 1999-12-23 2001-07-03 Millennium Pharmaceuticals, Inc. P2Y12 receptor
US20020012965A1 (en) 2000-01-12 2002-01-31 Strittmatter Stephen M. Nogo receptor-mediated blockade of axonal growth
AU785055B2 (en) * 2000-01-13 2006-09-07 Genentech Inc. Novel stra6 polypeptides
EP1252292A4 (de) * 2000-01-24 2004-11-17 Univ Ramot Gegenüber umweltstress bedingungen tolerante pflanzen, verfahren zur herstellung derselben sowie hierzu verwendete neuartige polynukleotidsequenzen
JP2003525038A (ja) 2000-02-08 2003-08-26 ユニバーシティー オブ ブリティッシュ コロンビア 治療薬をスクリーニングするための組成物および方法
JP2003527844A (ja) 2000-02-11 2003-09-24 ジェネンテック・インコーポレーテッド 血管形成及び心血管疾患の調節に使用する肝細胞成長因子の新規インヒビター
CA2396793A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US7276643B2 (en) * 2000-02-18 2007-10-02 The Regents Of The University Of California Transgenic animals, cell lines derived therefrom, and methods for screening for anti-amyloidogenic agents
EP1261712B1 (de) * 2000-03-03 2006-12-13 Curagen Corporation Fctrx genannte proteine und dafür kodierende nuklein säure
US7223395B2 (en) 2000-03-13 2007-05-29 Cornell Research Foundation, Inc. Blocking leukocyte emigration and inflammation by interfering with CD99/HEC2
US6740520B2 (en) 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
US20040086970A1 (en) * 2000-03-22 2004-05-06 Genentech, Inc. Novel cytokine receptors and nucleic acids encoding the same
EP1265849B1 (de) 2000-03-23 2006-10-25 Elan Pharmaceuticals, Inc. Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
WO2001073132A1 (en) 2000-03-27 2001-10-04 Thomas Jefferson University Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
CA2747325A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US20060015969A1 (en) * 2000-04-28 2006-01-19 Planet Biotechnology, Inc. Novel immunoadhesins for treating and prventing toxicity and pathogen-mediated diseases
WO2001083529A2 (en) * 2000-04-28 2001-11-08 Planet Biotechnology, Inc. Immunoadhesin for the prevention of rhinovirus infection
US20030219786A1 (en) * 2000-08-11 2003-11-27 Applied Research Systems Ars Holding N.V. Novel glycoproteins and methods of use thereof
US20040005554A1 (en) * 2000-05-08 2004-01-08 Tayar Nabil El Novel glycoproteins and methods of use thereof
AU2001265268A1 (en) * 2000-06-01 2001-12-11 Pharmacia And Upjohn Company Mice heterozygous for wfs1 gene as mouse models for depression
CA2648048A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2275549A1 (de) 2000-06-23 2011-01-19 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
AU2001271686A1 (en) 2000-06-30 2002-01-14 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
GB0016791D0 (en) 2000-07-07 2000-08-30 Novartis Ag Organic compounds
EP2075582A3 (de) 2000-07-12 2010-01-06 Agensys, Inc. Neuartiges Tumor-Antigen zur Diagnose und Therapie von Blasen-, Eierstock-, Lungen-, und Nierenkrebs
CA2415187C (en) * 2000-07-14 2013-06-18 David B. Weiner Dna vaccines encoding hiv accessory proteins
HUP0300810A2 (hu) 2000-07-20 2003-08-28 M.G.V.S. Ltd. Mesterséges értranszplantátum, valamint ennek létrehozása és alkalmazása
US20040023259A1 (en) * 2000-07-26 2004-02-05 Luca Rastelli Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
WO2002014473A2 (en) * 2000-08-15 2002-02-21 Board Of Trustees Of The University Of Illinois Animals expressing exogenous igf-i in their milk
US7198924B2 (en) * 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
EP2014298A3 (de) 2000-08-24 2009-10-07 Genentech, Inc. Interleukin-22-Polypeptide, Nukleinsäuren zu deren Codierung und Verfahren zur Behandlung von Bauchspeicheldrüsenerkrankungen
PT1313850E (pt) 2000-08-28 2008-11-18 Agensys Inc Ácido nucleico e proteína correspondente denominados 85p1b3 úteis no tratamento e na detecção de cancro
ATE448306T1 (de) 2000-09-01 2009-11-15 Blood Res Center Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung
EP1944317A3 (de) 2000-09-01 2008-09-17 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
US6673623B1 (en) 2000-09-12 2004-01-06 Novocure, Inc. Methods and compositions that control lipid production
US20030176344A1 (en) * 2000-09-14 2003-09-18 Decode Genetics Ehf. Human osteoporosis gene
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
JP2004526411A (ja) * 2000-09-18 2004-09-02 トマス・ジエフアーソン・ユニバーシテイ 胃および食道癌細胞を同定および標的とするための組成物および方法
ATE510908T1 (de) * 2000-09-28 2011-06-15 Bioriginal Food & Science Corp Fad5-2, mitglied der desaturase-familie und verwendungen davon
BR0115728A (pt) 2000-11-28 2003-09-23 Wyeth Corp Análise da expressão de ácidos nucléicos kiaa e polipeptìdeos úteis no diagnóstico e tratamento de cáncer de próstata
BR0115715A (pt) 2000-11-28 2004-02-03 Wyeth Corp Análise de expressão de ácidos nucleìcos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata
AU2002246758A1 (en) * 2000-12-29 2002-07-16 Vanderbilt University Epididymal lipocalin gene and uses thereof
US6964849B2 (en) 2001-01-11 2005-11-15 Curagen Corporation Proteins and nucleic acids encoding same
US20040043928A1 (en) * 2001-08-02 2004-03-04 Ramesh Kekuda Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030051266A1 (en) * 2001-02-14 2003-03-13 Serafini Tito Andrew Collections of transgenic animal lines (living library)
US20040215469A1 (en) * 2001-02-22 2004-10-28 Osamu Fukushima Content providing/acquiring system
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
WO2002075317A2 (en) * 2001-03-15 2002-09-26 Novartis Ag Screening for drugs against disorders associated with schizophrenia
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US20090081199A1 (en) * 2001-03-20 2009-03-26 Bioxell S.P.A. Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) * 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
CA2342376C (en) * 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
WO2002076196A1 (en) * 2001-03-22 2002-10-03 Abbott Gmbh & Co. Kg Transgenic animals expressing antibodies specific for genes of interest and uses thereof
CA2441594A1 (en) * 2001-03-22 2002-10-03 Scentgene Pollination Ltd. Method of enhancing entomophilous
EP2388590A1 (de) 2001-04-02 2011-11-23 Dana Farber Cancer Institute PD-1, ein Rezeptor für B7-4, und Verwendungen dafür
US20030148298A1 (en) * 2001-04-03 2003-08-07 O''toole Margot Methods for diagnosing and treating systemic lupus erythematosus disease and compositions thereof
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
CA2443123A1 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
EP2278013A1 (de) 2001-04-16 2011-01-26 Wyeth Holdings Corporation Polypeptidantigene codierende offene Leseraster aus Streptococcus Pneumoniae und Verwendungen davon
DE10121255A1 (de) * 2001-04-30 2002-11-07 Switch Biotech Ag Verwendung von alpha 1-Antichymotrypsin Polypeptiden oder diese kodierende Nukleinsäuren, oder einer ein ACT Polypeptid oder diese kodierende Nukleinsäure exprimierende Zelle, zur Behandlung und/oder Prävention von diabetes-assoziierten und/oder arteriellen schlecht heilenden Wunden und zur Identifizierung von pharmakologisch aktiven Substanzen
WO2002088180A2 (en) 2001-04-30 2002-11-07 Switch Biotech Ag Use of alpha 1-antichymotrypsin for the manufacture of a composition for treatment, prevention or diagnosis of poorly healing diabetic or arterial wounds
US20030017159A1 (en) * 2001-05-02 2003-01-23 Jerome Ritz Immunogenic tumor antigens: nucleic acids and polypeptides encoding the same and methods of use thereof
WO2002100317A2 (en) 2001-05-25 2002-12-19 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
WO2002099140A1 (en) 2001-06-05 2002-12-12 Exelixis, Inc. GLRAs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
MXPA03011260A (es) * 2001-06-07 2004-02-27 Wyeth Corp Receptor acoplado a proteina g y usos del mismo.
AU2002345670A1 (en) 2001-06-14 2003-01-02 The Regents Of The University Of California Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
US6949691B2 (en) 2001-06-15 2005-09-27 New Century Pharmaceuticals Inc. Human albumin animal models for drug evaluation, toxicology and immunogenicity studies
MXPA03011985A (es) 2001-06-20 2004-03-26 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
US20030013081A1 (en) 2001-06-26 2003-01-16 Olson William C. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
MXPA04000140A (es) * 2001-06-27 2004-06-03 Elan Pharm Inc Derivados de beta-hidroxiamina utiles en el tratamiento de enfermedad de alzheimer.
US20030129613A1 (en) * 2001-07-05 2003-07-10 Fernandes Elma R. Novel human proteins and polynucleotides encoding them
US20030087274A1 (en) * 2001-07-05 2003-05-08 Anderson David W. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040029790A1 (en) * 2001-07-05 2004-02-12 Meera Patturajan Novel human proteins, polynucleotides encoding them and methods of using the same
JP4837888B2 (ja) * 2001-07-23 2011-12-14 ザ ジェネラル ホスピタル コーポレイション コンホメーションが拘束された副甲状腺ホルモン（ｐｔｈ）類似体
US6867189B2 (en) * 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
US20040030096A1 (en) * 2001-08-02 2004-02-12 Linda Gorman Novel human proteins, polynucleotides encoding them and methods of using the same
US20030027258A1 (en) * 2001-08-02 2003-02-06 Chang Fang-Tseh Frank Methods and compositions for pearl oyster cultivation
US20030119771A1 (en) * 2001-08-22 2003-06-26 Rompaey Luc Van Modulators of bone homeostasis identified in a high-throughput screen
AU2002336446B2 (en) 2001-09-06 2008-03-06 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
ES2390531T3 (es) 2001-09-18 2012-11-13 Genentech, Inc. Composiciones y procedimientos para el diagnósitco y tratamiento de tumor
US20040023910A1 (en) * 2001-09-28 2004-02-05 Zhiming Zhang Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
US20030199442A1 (en) * 2001-10-09 2003-10-23 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20070118934A1 (en) * 2001-10-26 2007-05-24 Planet Biotechnology, Inc. Chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax
WO2003038118A1 (fr) 2001-10-31 2003-05-08 Fujisawa Pharmaceutical Co., Ltd. Methode d'evaluation d'inhibiteurs de la phosphatase
CA2466415C (en) 2001-11-09 2020-01-21 Dana-Farber Cancer Institute, Inc. Pgc-1.beta., a novel pgc-1 homologue and uses therefor
WO2003048298A2 (en) * 2001-12-05 2003-06-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nanoparticles containing polymeric nucleic acid homologs, pharmaceutical compositions and articles of manufacture containing same and methods of use thereof
WO2003050262A2 (en) 2001-12-10 2003-06-19 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
WO2003052120A2 (en) * 2001-12-14 2003-06-26 President And Fellows Of Harvard College Dual inhibition of sister chromatide separation at metaphase
JP2005527191A (ja) * 2001-12-18 2005-09-15 アンドキューブ ソシエタ パー アクシオン シンプリフィー 新規の細胞死関連タンパク質ならびにアポトーシス制御におけるｔｈａｐ１およびｐａｒ４の経路
US7858297B2 (en) * 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
EP2067472A1 (de) 2002-01-02 2009-06-10 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
CN101166762A (zh) 2002-02-07 2008-04-23 达尔塔生物技术有限公司 白蛋白融合的Kunitz结构域肽
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1575480A4 (de) 2002-02-22 2008-08-06 Genentech Inc Zusammensetzungen und verfahren zur behandlung von immunbedingten erkrankungen
EP1485477B1 (de) 2002-02-25 2009-05-13 Genentech, Inc. Neuer typ-1-cytokinrezeptor glm-r
DE60325519D1 (de) * 2002-03-01 2009-02-12 Hoffmann La Roche Doppel-transgenisches, nicht-humanes Säugertiermodell für die Alzheimer Krankheit
US7153685B2 (en) * 2002-03-11 2006-12-26 The Board Of Trustees Of The University Of Illinois Tamoxifen and 4-hydroxytamoxifen-activated system for regulated production of proteins in eukaryotic cells
NZ535925A (en) 2002-04-16 2008-06-30 Genentech Inc An isolated antibody that binds to a particular polypeptide
JP2005523712A (ja) * 2002-04-29 2005-08-11 トマス ジェファソン ユニバーシティ 標的ｔｃｌ１発現によりマウスでモデル化されたヒト慢性リンパ球性白血病
EP2305710A3 (de) 2002-06-03 2013-05-29 Genentech, Inc. Synthetische Antikörperphagenbibliotheken
EP1553912A4 (de) * 2002-06-07 2007-08-08 Genentech Inc Zusammensetzungen und verfahren f r die tumordiagnose und behandlung
JP4654029B2 (ja) 2002-06-17 2011-03-16 トラソス インコーポレイテッド 単一ドメインｔｄｆ関連化合物およびその類似体
US20040005571A1 (en) * 2002-07-03 2004-01-08 Hawley R. Scott Axs gene and protein and methods related thereto
WO2004004649A2 (en) 2002-07-08 2004-01-15 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7250551B2 (en) * 2002-07-24 2007-07-31 President And Fellows Of Harvard College Transgenic mice expressing inducible human p25
AU2003261366A1 (en) * 2002-08-05 2004-02-23 The Wistar Institute Methods for regulating brca1-brca2-containing complex activity
US20050271637A1 (en) * 2002-08-16 2005-12-08 Bodine Peter Van N BMP-2 estrogen responsive element and methods of using the same
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
WO2004018999A2 (en) 2002-08-20 2004-03-04 Millenium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
US7135324B2 (en) * 2002-09-04 2006-11-14 The University Of Connecticut Viral recombinases, related articles, and methods of use thereof
EP1539228B1 (de) 2002-09-11 2010-12-29 Genentech, Inc. Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
AU2003276874B2 (en) 2002-09-11 2009-09-03 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
US20070010434A1 (en) 2002-09-16 2007-01-11 Genetech, Inc. Novel compositions and methods for the treatment of immune related diseases
CA2500224C (en) 2002-09-25 2015-04-28 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
EP2500438A3 (de) 2002-09-25 2012-11-28 Genentech, Inc. Neue Zusammensetzungen und Verfahren zur Behandlung von Psoriasis
JP2006500074A (ja) * 2002-09-27 2006-01-05 オリディス・ビオメド・フォルシュングス−ウント・エントヴィックルングス・ゲーエムベーハー ポリペプチドおよびこれらをコード化する核酸ならびに肝臓障害および上皮癌の防止、診断、または処置のためのその使用
KR20050049545A (ko) * 2002-10-14 2005-05-25 에프. 호프만-라 로슈 아게 길항제 ｉｌ-15
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
EP1558737A4 (de) 2002-10-18 2008-06-11 Lg Life Sciences Ltd Mit krebserkrankungen assoziierte genfamilien
AU2003284968A1 (en) * 2002-10-25 2004-05-13 University Of South Florida Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
EP2322201A3 (de) 2002-10-29 2011-07-27 Genentech, Inc. Gestaltungen und Methoden für die behandlung von Immune verwandte Krankheiten
JP2006515318A (ja) * 2002-10-29 2006-05-25 ファルマシア・コーポレーション 特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法
WO2004042363A2 (en) * 2002-11-04 2004-05-21 Dana-Farber Cancer Institute, Inc. In vivo imaging of e2f-regulated bioluminescent proteins
CA2503748A1 (en) 2002-11-08 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
EP1572730A4 (de) * 2002-11-22 2006-04-19 Med College Georgia Res Inst Nact als target für die verlängerung derlebensspanne und gewichtsreduktion
JP2011516026A (ja) 2002-11-26 2011-05-26 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
EP1578767A4 (de) * 2002-12-04 2008-01-09 Algos Therapeutics Inc Verfahren und materialien zur modulation von trpm2
AU2003299441A1 (en) * 2002-12-19 2004-07-14 Centre National De La Recherche Scientifique - Cnrs Nf-hev compositions and methods of use
JP5479663B2 (ja) 2002-12-20 2014-04-23 セレラ コーポレーション 心筋梗塞に関連する遺伝的多型、その検出方法および使用
US20040194156A1 (en) * 2002-12-27 2004-09-30 Califa Llc Transgenic aquatic invertebrates as a bioreactor for production of recombinant polypeptides
AU2003292681A1 (en) * 2002-12-27 2004-07-29 Chugai Seiyaku Kabushiki Kaisha Wt1 transgenic animal
EP2343315A3 (de) 2003-02-10 2011-11-23 Agensys, Inc. Nukleinsäure und entsprechendes Protein mit der Bezeichnung 158P1D7, das sich für die Behandlung und den Nachweis von Blasenkrebs und anderen Krebserkrankungen eignet
JP4334480B2 (ja) * 2003-03-19 2009-09-30 ザ ジェネラル ホスピタル コーポレイション α−ヘリックス安定化剤を用いる高次構造的に制約された副甲状腺ホルモン
US20040241657A1 (en) * 2003-05-28 2004-12-02 Perlegen Sciences, Inc. Liver related disease compositions and methods
US20050069918A1 (en) * 2003-05-29 2005-03-31 Francois Claret JAB1 as a prognostic marker and a therapeutic target for human cancer
US7514593B2 (en) * 2003-05-30 2009-04-07 The University Of North Carolina At Chapel Hill Animal model for chronic obstructive pulmonary disease and cystic fibrosis
ATE541052T1 (de) 2003-05-30 2012-01-15 Agensys Inc Varianten des prostata-stammzellen-antigens (psca) und teilsequenzen davon
US7097993B2 (en) * 2003-06-25 2006-08-29 Wisconsin Alumni Research Foundation Method for identifying an agent that modulates type 1 phosphatidylinositol phosphate kinase isoform β661 activity
KR100835786B1 (ko) 2003-07-08 2008-06-09 제넨테크, 인크. Ｉｌ-１７ａ／ｆ 이종 폴리펩티드 및 그의 치료 용도
EP1653985A4 (de) 2003-07-17 2009-08-05 Gen Hospital Corp Zwangsform-parathormon (pth)-analoga
WO2005010039A1 (en) * 2003-07-31 2005-02-03 Pfizer Products Inc. Bsep polypeptide variants and uses thereof
US20050069929A1 (en) 2003-08-08 2005-03-31 Invitrogen Corporation Methods and compositions for seamless cloning of nucleic acid molecules
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2535897A1 (en) 2003-08-14 2005-02-24 Exelixis, Inc. Sulfs as modifiers of the beta catenin pathway and methods of use
US7354734B2 (en) 2003-08-25 2008-04-08 Funzyme Biotechnologies Sa Fungal proteins and nucleic acids encoding same
EP1670924A1 (de) * 2003-08-28 2006-06-21 Aveo Pharmaceuticals, Inc. Tumorspezifische expression von reportergenen
ES2453895T3 (es) 2003-09-23 2014-04-08 University Of North Carolina At Chapel Hill Células que expresan vitamina K epóxido reductasa y uso de las mismas
WO2005034732A2 (en) 2003-10-07 2005-04-21 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US20070274988A1 (en) * 2003-10-10 2007-11-29 Five Prime Therapeautics, Inc. Kiaa0779, Splice Variants Thereof, and Methods of Their Use
EP2272951B1 (de) 2003-10-14 2014-07-23 Baxter International Inc. VKCORC1 (vitamin k epoxide recycling polypeptide), ein therapeutisches Ziel für Coumarin und deren Derivate
EP1681988B1 (de) 2003-11-12 2015-04-08 The Children's Hospital Medical Center Verfahren zur diagnose und behandlung von lungenerkrankungen
JP4901478B2 (ja) 2003-11-17 2012-03-21 ジェネンテック， インコーポレイテッド 造血系起源の腫瘍の治療のための組成物と方法
US20050120397A1 (en) * 2003-11-24 2005-06-02 Hermann Steller Compounds and methods for regulation of spermatid differentiation
JP5649263B2 (ja) 2003-11-26 2015-01-07 セレラ コーポレーション 心臓血管障害および薬物応答に関連した遺伝子多型、それらの検出方法および用途
EP2287341B1 (de) 2003-12-01 2013-02-13 Life Technologies Corporation Rekombinationsstellen enthaltende Nukleinsäuremoleküle und Verfahren zur Verwendung davon
US7371539B2 (en) * 2003-12-03 2008-05-13 President And Fellows Of Harvard College Targeted polypeptide degradation
CN1938333A (zh) * 2003-12-03 2007-03-28 达尔塔生物技术有限公司 白介素－11融合蛋白
WO2005059100A2 (en) * 2003-12-12 2005-06-30 New York University Methods and compositions relating to cystatin c
EP1711517A4 (de) 2004-01-21 2008-02-13 Univ Utah Res Found MUTANTER NATRIUMKANAL NAv1.7 UND DAMIT VERBUNDENE VERFAHREN
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20050272678A1 (en) * 2004-02-11 2005-12-08 Bodine Peter Van N BMP-6 estrogen responsive element and methods of use thereof
CN104774931B (zh) 2004-03-31 2017-11-10 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
US20060019241A1 (en) * 2004-04-20 2006-01-26 Vadivel Ganapathy Na+ and CI-coupled transport system for endogenous opioid peptides
EP2423327B1 (de) 2004-05-07 2014-01-08 Celera Corporation Genetischer Polymorphismus und Leberfibrose, Verfahren zur Erkennung und Verwendung davon
US20060014934A1 (en) * 2004-05-18 2006-01-19 Everse Stephen J Crystal structure of factor Vai and method for identifying blood factor Va modulators
WO2005115992A1 (en) 2004-05-23 2005-12-08 Housey Pharmaceuticals, Inc. Theramutein modulators
EP2583981A3 (de) 2004-05-28 2013-07-31 Agensys, Inc. An PSCA-Proteine bindende Antikörper und zugehörige Moleküle
ES2535229T3 (es) 2004-06-10 2015-05-06 Viventia Bio Inc. Anticuerpo específico de tumor
EP2319526A1 (de) 2004-06-17 2011-05-11 Thrasos Therapeutics, Inc. TDF-ähnliche Verbindungen und deren Analogal
US7288385B2 (en) 2004-06-25 2007-10-30 The Salk Institute For Biological Studies Increasing life span by modulation of Smek
US7968762B2 (en) 2004-07-13 2011-06-28 Van Andel Research Institute Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
US20070264277A1 (en) 2004-07-22 2007-11-15 Dirk Behrens Compositions and Methods of Use for Mgd-Csf in Disease Treatment
EP2484780A1 (de) 2004-07-23 2012-08-08 The University of North Carolina At Chapel Hill Verfahren und Materialien zur Bestimmung der Schmerzempfindlichkeit und Vorhersage und Behandlung zugehöriger Störungen
EP1789437A4 (de) * 2004-07-30 2008-11-05 Sinai School Medicine Npc1l1 und npc1l1-inhibitoren und verfahren zu deren anwendung
DE102004037860A1 (de) * 2004-08-04 2006-03-16 Friedrich-Alexander-Universität Erlangen-Nürnberg Turmormarker zur Diagnose von Karzinomen und/oder davon abstammender Metastasen
US20060031945A1 (en) * 2004-08-06 2006-02-09 Yu Shen Inducible expression systems for modulating the expression of target genes in eukaryotic cells and non-human animals
WO2006021896A2 (en) 2004-08-27 2006-03-02 Tripep Ab Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics
WO2006055836A2 (en) * 2004-11-16 2006-05-26 President And Fellows Of Harvard College In vivo alteration of cellular dna
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
SI1839120T1 (sl) 2004-12-21 2013-12-31 Janssen Biotech, Inc. Vektorji na osnovi protitelesa anti-il-12, gostiteljske celice in postopki proizvodnje ter uporabe
US20060154285A1 (en) * 2004-12-29 2006-07-13 Robishaw Janet D Zebrafish heterotrimer G-protein gamma 2 subunit (GNG2)
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
CA2600794C (en) 2005-03-11 2014-08-12 Applera Corporation Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
AU2005329450A1 (en) 2005-03-15 2006-09-28 University Of North Carolina At Chapel Hill Methods and compositions for producing active Vitamin K-dependent proteins
AU2006230563B8 (en) 2005-03-31 2010-06-17 Agensys, Inc. Antibodies and related molecules that bind to 161P2F10B proteins
US20070061899A1 (en) * 2005-04-13 2007-03-15 The Trustees Of Columbia University In The City Of New York Transgenic mammal with constitutive, tissue-specific cytokine expression and use as a cancer model
EP2399932B1 (de) 2005-05-12 2016-11-16 ZymoGenetics, Inc. Zusammensetzungen und Verfahren zur Modulation von Immunantworten
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
WO2006132788A2 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
EP2343363A1 (de) 2005-07-01 2011-07-13 John Schrader Verfahren zur Isolierung von Zellen und Erzeugung monoklonaler Antikörper unter Verwendung einer Einzel-Epitop Mehrfach-Färbung
WO2007005898A2 (en) * 2005-07-05 2007-01-11 Cornell Research Foundation, Inc. Blocking leukocyte emigration and inflammation by interfering with cd99l2
CA2614039C (en) 2005-07-22 2015-10-13 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
EP1924686A4 (de) 2005-08-09 2009-11-11 Revivicor Inc Ctla4-ig exprimierende transgene huftiere und deren verwendung
AU2006280321A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
AU2006287315B2 (en) 2005-09-09 2013-02-21 The Johns Hopkins University Manipulation of regulatory T cell and DC function by targeting neuritin gene using antibodies, agonists and antagonists
CA2623106C (en) 2005-09-19 2013-12-24 Histogenics Corporation Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof
SI2497780T1 (sl) 2005-09-20 2015-08-31 Thrasos Innovation, Inc. Spojine, povezane s TDF, in njihovi analogi
US7799530B2 (en) 2005-09-23 2010-09-21 Celera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
DE102005048898A1 (de) * 2005-10-12 2007-04-19 Sanofi-Aventis Deutschland Gmbh EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen
DE602006019128D1 (de) * 2005-11-10 2011-02-03 Bristol Myers Squibb Pharma Co Moesin, caveolin 1 und yes-assoziiertes protein 1 als prädiktive marker der reaktion auf dasatinib bei brustkrebs
AU2006335053A1 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
CN103789389B (zh) * 2005-11-23 2017-01-04 杰勒德·M·豪斯 鉴定、合成、优化和表征蛋白调节剂的化合物和方法
WO2007070252A2 (en) * 2005-11-30 2007-06-21 The University Of North Carolina At Chapel Hill Identification of genetic polymorphic variants associated with somatosensory disorders and methods of using the same
CA2633468C (en) 2005-12-14 2014-02-18 Licentia Ltd Novel neurotrophic factor protein and uses thereof
CN101384623B (zh) * 2005-12-22 2013-07-24 常山凯捷健生物药物研发（河北）有限公司 白蛋白与治疗剂的预成型偶联物的制备方法
DK1973545T3 (da) 2005-12-23 2013-02-25 Ariad Pharma Inc Bicykliske heteroarylforbindelser
JP2009525110A (ja) 2006-01-31 2009-07-09 マルチ ジーン バスキュラー システムズ， インコーポレイテッド 薬物溶出血管内プロテーゼおよび使用方法
US20070186296A1 (en) * 2006-02-02 2007-08-09 Wyeth Cloning, characterization, and application of tnfrsf19 in neurological disorders
WO2007114979A2 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
CN101400349A (zh) * 2006-03-01 2009-04-01 罗斯坎普研究有限责任公司 抑制β-淀粉样蛋白产生的化合物
US20070250941A1 (en) * 2006-03-27 2007-10-25 Genentech, Inc. VEGF Receptor Conditional Knockout Animals and Methods of Use
US20090288176A1 (en) 2006-04-19 2009-11-19 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
US8933209B2 (en) 2006-04-26 2015-01-13 Abbvie Inc. Dep2 and its uses in major depressive disorder and other related disorders
US20070256148A1 (en) * 2006-04-26 2007-11-01 Katz David A DEP2 and its uses in major depressive disorder and other related disorders
EP2029749A2 (de) 2006-05-15 2009-03-04 Paratek Pharmaceuticals, Inc. Verfahren zur regulierung der expression von genen oder genprodukten mittels substituierter tetracyclinverbindungen
EP2035439A4 (de) 2006-06-05 2010-01-13 Cancer Care Ontario Abschätzung des risikos von colorectalkrebs
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP1873527A1 (de) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Verfahren zur Identifizierung von CRMP-Modulatoren
US8124831B2 (en) * 2006-07-06 2012-02-28 Duke University Transgenic mice carrying functional single nucleotide polymorphisms in brain-specific tryptophan hydroxylase
US8143374B2 (en) * 2006-08-04 2012-03-27 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (PTH)
EP2054437A2 (de) * 2006-08-07 2009-05-06 Teva Biopharmaceuticals USA, Inc. Albumin-insulin-fusionsproteine
WO2008019394A2 (en) * 2006-08-11 2008-02-14 The Government Of The United States Of America As Represented By The Secretary, Dept Of Health And Human Services Methods for treatment and diagnosis of psychiatric disorders
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
EP2639318B1 (de) 2006-09-11 2015-04-08 Celera Corporation Psoriaseassoziierte genetische Polymorphismen, Nachweisverfahren dafür und ihre Verwendung
AU2007294858B2 (en) 2006-09-14 2011-05-12 Medgenics Medical Israel, Ltd Long lasting drug formulations
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
US8680235B2 (en) * 2006-09-22 2014-03-25 Stowers Institute For Medical Research Branchiostoma derived fluorescent proteins
CA2915679C (en) 2006-10-20 2017-12-12 Celera Corporation Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof
WO2008153543A2 (en) * 2006-10-27 2008-12-18 Stowers Institute For Medical Research Fluorescent mouse model
US20100119599A1 (en) * 2006-12-08 2010-05-13 Archer Pharmaceuticals, Inc. Polyhydroquinoline compounds and dihydropyridine compounds for inhibiting beta-amyloid production
US20080188573A1 (en) * 2007-02-02 2008-08-07 Alcon Research, Ltd. Use of thy1-fp transgenic mouse for the identification of ophthalmic agents
AU2008222563A1 (en) 2007-03-05 2008-09-12 Cancer Care Ontario Assessment of risk for colorectal cancer
WO2008152507A2 (en) 2007-03-16 2008-12-18 Multigene Vascular Systems, Inc. Compositions and methods for treating ophthalmic disorders
EP1975228A1 (de) 2007-03-28 2008-10-01 Fachhochschule Mannheim Polynukleotide für verstärkte Expression eines relevanten Polynukleotids
US20100158927A1 (en) 2007-03-29 2010-06-24 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
WO2008130668A2 (en) * 2007-04-20 2008-10-30 Mt. Sinai School Of Medicine Of New York University Mo-1, a gene associated with morbid obesity
CA2687787A1 (en) * 2007-05-21 2008-12-18 Dana Farber Cancer Institute, Inc. Compositions and methods for cancer gene discovery
WO2008154251A2 (en) 2007-06-07 2008-12-18 Genentech, Inc. C3b antibodies and methods for the prevention and treatment of complement- associated disorders
EP2006376A1 (de) * 2007-06-21 2008-12-24 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Fusionsprotein mit einer Caspasedomäne und einer nuklearen Hormonrezeptor bindenden Domäne sowie Verfahren und Verwendungen davon
CA2694667C (en) * 2007-08-01 2018-10-30 The General Hospital Corporation Screening methods using g-protein coupled receptors and related compositions
US8039212B2 (en) 2007-11-05 2011-10-18 Celera Corporation Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
WO2009061910A1 (en) 2007-11-08 2009-05-14 Genetech, Inc. Anti-factor b antibodies and their uses
CA2705152C (en) 2007-11-09 2016-10-11 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
WO2009088876A2 (en) 2007-12-31 2009-07-16 Baxter International Inc. Transgenic non-human animals expressing human blood clotting factors and uses thereof
KR101932831B1 (ko) 2008-01-31 2018-12-27 반더빌트유니버시티 관상과 동맥의 동맥류성 지주막하출혈의 치료를 위한 조성물 및 방법
CN101969974A (zh) * 2008-01-31 2011-02-09 范德比尔特大学 对于肺部病症的治疗
US20090221620A1 (en) 2008-02-20 2009-09-03 Celera Corporation Gentic polymorphisms associated with stroke, methods of detection and uses thereof
EP3369827B1 (de) 2008-03-12 2020-12-23 The Rockefeller University Verfahren und zusammensetzungen zur translationalen profilierung und molekularen phänotypisierung
US8288094B2 (en) * 2008-04-09 2012-10-16 Institut Pasteur APOBEC3 mediated DNA editing
CN104655854A (zh) 2008-04-09 2015-05-27 健泰科生物技术公司 用于免疫相关疾病的治疗的新组合物和方法
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
LT2300013T (lt) 2008-05-21 2017-12-27 Ariad Pharmaceuticals, Inc. Fosforo dariniai kaip kinazių inhibitoriai
EP2733222A1 (de) 2008-07-09 2014-05-21 Celera Corporation Mit kardiovaskulären Krankheiten assoziierte, genetische Polymorphismen, Verfahren zum Nachweis und Verwendungen davon
US8709758B2 (en) * 2008-07-28 2014-04-29 University Of Louisville Research Foundation, Inc. Methods and compositions for inhibition of neutrophil exocytosis
US8241846B1 (en) 2008-09-08 2012-08-14 Institut De Recherches Cliniques De Montreal Hedgehog pathway modulation and uses thereof for treating, preventing and/or diagnosing cancer
US20110206736A1 (en) * 2008-09-23 2011-08-25 Thomas Jefferson University Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same
JP5576382B2 (ja) 2008-10-01 2014-08-20 テット・システムズ・ゲーエムベーハー・ウント・カンパニー・カーゲー テトラサイクリン誘導可能な転写制御配列
JP5749649B2 (ja) * 2008-10-27 2015-07-15 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 血栓性血小板減少性紫斑病のモデルおよびその使用方法
CA2743449C (en) 2008-11-12 2016-10-18 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
WO2010071836A1 (en) 2008-12-19 2010-06-24 Inserm Il-15 mediated nk and t cell maturation
US9181315B2 (en) 2009-01-08 2015-11-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
WO2010083328A2 (en) 2009-01-14 2010-07-22 The Salk Institute For Biological Studies Methods for screening and compounds that protect against amyloid diseases
US8008539B1 (en) 2009-03-19 2011-08-30 University Of South Florida Generation of transgenic human soluble amyloid precursor protein alpha expressing mice
US20120094312A1 (en) 2009-04-03 2012-04-19 Institut Pasteur Boosting human dendritic cell development, homeostasis and function in xenografted immunodeficient mice
WO2010124200A2 (en) * 2009-04-23 2010-10-28 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for cancer
WO2010147803A2 (en) 2009-06-08 2010-12-23 Regents Of The University Of Michigan Adult cerebellum-derived neural stem cells and compositions and methods for producing oligodendrocytes
GB0909906D0 (en) 2009-06-09 2009-07-22 Affitech As Antibodies
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
EP2261242A1 (de) 2009-06-10 2010-12-15 Universite Catholique De Louvain Aspartat-N-Acetyltransferaseenzym, Diagnoseverfahren und therapeutisches Verfahren
EP2449112A1 (de) 2009-07-01 2012-05-09 Transposagen Biopharmaceuticals, Inc. Genetisch modifizierte rattenmodelle für schwere kombinierte immundefizienz (scid)
US8558055B2 (en) 2009-07-24 2013-10-15 Transposagen Biopharmaceuticals, Inc. Genetically modified rat comprising a cytokine gene disruption and exhibiting a greater susceptibility to a cytokine-mediated autoimmune and/or inflammatory disease
WO2011014721A2 (en) 2009-07-30 2011-02-03 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for pharmacokinetics
EP2462231A2 (de) 2009-08-04 2012-06-13 Baxter International Inc Transgene maus mit mangel an endogenem fviii und vwf - ein modell für hämophilie a
EP2461672A2 (de) * 2009-08-05 2012-06-13 Transposagen Biopharmaceuticals, Inc. Genetisch modifizierte rattenmodelle für arzneimittelstoffwechsel
EP2467013A2 (de) 2009-08-20 2012-06-27 Transposagen Biopharmaceuticals, Inc. Genetisch modifizierte rattenmodelle für schmerz
DK3056082T3 (en) 2009-10-06 2018-12-17 Regeneron Pharma RE-MODIFIED MICE AND INPUT
JP5955771B2 (ja) 2009-10-22 2016-07-20 トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ 細胞ベースの抗癌組成物ならびに当該物の製造方法および使用方法
RU2539772C2 (ru) 2009-10-22 2015-01-27 Дженентек, Инк. Способы и композиции для модуляции гепсином стимулирующего макрофаги белка
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
JP6007420B2 (ja) 2009-11-04 2016-10-12 ファブラス エルエルシー 親和性成熟に基づく抗体最適化方法
PE20121584A1 (es) 2009-11-30 2012-11-29 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores
US20110159588A1 (en) 2009-12-30 2011-06-30 Kui Lin Methods for Modulating a PDGF-AA Mediated Biological Response
US10429384B2 (en) 2010-01-22 2019-10-01 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
TWI518325B (zh) 2010-02-04 2016-01-21 自治醫科大學 對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
GB201002238D0 (en) 2010-02-10 2010-03-31 Affitech As Antibodies
KR20130004579A (ko) 2010-02-23 2013-01-11 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
CN103119054B (zh) 2010-03-26 2017-01-18 达特茅斯大学理事会 Vista调节性t细胞介体蛋白、vista结合剂及其用途
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
US20110269735A1 (en) 2010-04-19 2011-11-03 Celera Corporation Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
JP6073217B2 (ja) 2010-04-29 2017-02-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ゲノムモデルに関するデータ統合を用いたパスウェイ認識アルゴリズム（ｐａｒａｄｉｇｍ）
CN107090045A (zh) 2010-05-03 2017-08-25 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
WO2011143406A2 (en) 2010-05-13 2011-11-17 The General Hospital Corporation Parathyroid hormone analogs and uses thereof
US9646134B2 (en) 2010-05-25 2017-05-09 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
AU2011258875B2 (en) 2010-05-25 2016-05-05 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
JP2013532152A (ja) 2010-06-15 2013-08-15 メドジェニクス・メディカル・イスラエル・リミテッド 長期持続性の医薬製剤
US20120108651A1 (en) 2010-11-02 2012-05-03 Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL) Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
WO2012088222A2 (en) 2010-12-21 2012-06-28 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
AU2012217792A1 (en) 2011-02-14 2013-08-29 Revivicor, Inc. Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof
KR102390850B1 (ko) 2011-02-15 2022-04-26 리제너론 파마슈티칼스 인코포레이티드 인간화된 ｍ－ｃｓｆ 마우스
WO2012129198A1 (en) 2011-03-23 2012-09-27 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for obesity and diabetes
US9701742B2 (en) 2011-07-01 2017-07-11 The Trustees Of The University Of Pennsylvania Anti-properdin antibodies and uses thereof
WO2013039996A1 (en) 2011-09-13 2013-03-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using fndc5
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
DK2814844T3 (da) 2012-02-15 2017-11-13 Novo Nordisk As Antistoffer, der binder og blokerer udløsende receptor udtrykt på myeloide celler-1 (trem-1)
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
RS57827B1 (sr) 2012-02-15 2018-12-31 Novo Nordisk As Antitela koja vezuju protein 1 prepoznavanja peptidoglikana
WO2013133708A1 (en) 2012-03-07 2013-09-12 Stichting Vu-Vumc Compositions and methods for diagnosing and treating intellectual disability syndrome, autism and autism related disorders
US9540657B2 (en) 2012-05-25 2017-01-10 California Institute Of Technology Expression of secreted and cell-surface polypeptides
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
JP6285923B2 (ja) 2012-06-22 2018-02-28 トラスティーズ・オブ・ダートマス・カレッジ 新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用
US9265238B2 (en) 2012-08-31 2016-02-23 Lisa Porter MMTV-SV40-Spy1A and Spy1A-pTRE transgenic mouse models
US9185890B2 (en) 2012-08-31 2015-11-17 Lisa Porter MMTV-SV40-Spy1A and Spy1A-pTRE transgenic mouse models
US10251379B2 (en) 2012-08-31 2019-04-09 University Of Windsor MMTV-SV40-Spy1A and Spy1A-pTRE transgenic mouse models
AU2013312211B2 (en) 2012-09-07 2018-03-29 King's College London VISTA modulators for diagnosis and treatment of cancer
PT2892330T (pt) 2012-09-07 2023-02-17 Institute For Res In Biomedicine Irb Ratinhos geneticamente modificados e métodos de utilização dos mesmos
AU2013337242B2 (en) 2012-11-05 2019-04-04 Institute For Research In Biomedicine (Irb) Genetically modified non-human animals and methods of use thereof
PE20151673A1 (es) 2013-03-15 2015-11-27 Genentech Inc POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
WO2014191630A2 (en) 2013-05-28 2014-12-04 Helsingin Yliopisto Non-human animal model encoding a non-functional manf gene
CA2922561C (en) 2013-09-12 2023-03-14 Icahn School Of Medicine At Mount Sinai T cell receptors that are specific to a fluorescent protein, transgenic animals and methods of their making, isolated t cells, and methods of use
WO2015059701A1 (en) 2013-10-24 2015-04-30 Medgenics Medical Israel Ltd. Micro-organs providing sustained delivery of a therapeutic polypeptide and methods of use thereof
EP3087098B1 (de) 2013-12-24 2020-04-08 Janssen Pharmaceutica NV Anti-vista-antikörper und -fragmente
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
US20150327523A1 (en) 2014-05-13 2015-11-19 University Of South Florida Transgenic mouse model for conditional fkbp51 expression and related methods
EP3145307B1 (de) 2014-05-19 2019-02-06 Regeneron Pharmaceuticals, Inc. Genetisch modifizierte nichtmenschliche tiere zur expression von menschlichem epo
CN107073109B (zh) 2014-06-11 2021-08-06 凯西·A·格林 Vista激动剂和拮抗剂抑制或增强体液免疫的用途
CN106536559B (zh) 2014-07-17 2021-04-27 诺和诺德股份有限公司 定点诱变trem-1抗体以降低黏度
KR102331856B1 (ko) 2014-10-21 2021-11-29 다케다 야쿠힌 고교 가부시키가이샤 결정 형태의 5-클로로-n4-[2-(디메틸포스포릴)페닐]-n2-｛2-메톡시-4-[4-(4-메틸피페라진-1-일)피페리딘-1-일]피리미딘-2,4-디아민
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
EP3226900A4 (de) 2014-12-05 2018-09-19 Immunext, Inc. Identifizierung von vsig8 als vermeintlicher vista-rezeptor und dessen verwendung zur herstellung von vista/vsig8-modulatoren
US11446366B2 (en) 2015-02-05 2022-09-20 Canem Holdings, Llc Compositions and methods for treating granulomatosis with polyangiitis
DK3282835T3 (da) 2015-04-13 2023-06-26 Regeneron Pharma Humaniserede SIRP?-IL-15-knockin-mus og fremgangsmåder til anvendelse deraf
WO2016207717A1 (en) 2015-06-24 2016-12-29 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
US11913166B2 (en) 2015-09-21 2024-02-27 Modern Meadow, Inc. Fiber reinforced tissue composites
WO2017075329A2 (en) 2015-10-29 2017-05-04 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
EP3943090A1 (de) 2016-01-29 2022-01-26 Massachusetts Eye & Ear Infirmary Expansion und differenzierung von innenohrunterstützenden zellen und verfahren zur verwendung davon
MX2018009800A (es) 2016-02-12 2018-11-09 Janssen Pharmaceutica Nv Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos.
BR112017016266A2 (pt) 2016-02-15 2018-03-27 Modern Meadow, Inc. método para produzir um material biofabricado.
EP3442579A4 (de) 2016-04-15 2019-12-18 Immunext Inc. Anti-human-vista-antikörper und verwendung davon
CA3008850A1 (en) 2017-06-29 2018-12-29 Modern Meadow, Inc. Yeast strains and methods for producing collagen
AU2018253595A1 (en) 2017-11-13 2019-05-30 Modern Meadow, Inc. Biofabricated leather articles having zonal properties
SG11202009625WA (en) 2018-04-02 2020-10-29 Bristol Myers Squibb Co Anti-trem-1 antibodies and uses thereof
EP3704202A4 (de) 2019-01-17 2020-12-16 Modern Meadow, Inc. Geschichtete kollagenmaterialien und verfahren zu ihrer herstellung
CA3162639A1 (en) 2019-11-05 2021-05-14 Versiti Blood Research Institute Foundation, Inc. A murine model of fetal/neonatal alloimmune thrombocytopenia
US11266129B2 (en) 2019-11-05 2022-03-08 Versiti Blood Research Institute Foundation, Inc. Murine model of fetal/neonatal alloimmune thrombocytopenia
AU2021385081A1 (en) 2020-11-20 2023-06-29 Revivicor, Inc. Multi-transgenic pigs with growth hormone receptor knockout for xenotransplantation
WO2022204067A1 (en) 2021-03-24 2022-09-29 Dna Twopointo Inc. Tetracycline-inducible expression systems
CA3217862A1 (en) 2021-05-05 2022-11-10 Radius Pharmaceuticals, Inc. Animal model having homologous recombination of mouse pth1 receptor
US20230255185A1 (en) 2021-09-20 2023-08-17 Revivicor, Inc. Multitransgenic pigs comprising ten genetic modifications for xenotransplantation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535058A (en) * 1982-10-01 1985-08-13 Massachusetts Institute Of Technology Characterization of oncogenes and assays based thereon
US4579821A (en) * 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription

Also Published As

Publication number Publication date
JPS6181743A (ja) 1986-04-25
EP0169672A1 (de) 1986-01-29
EP0169672B1 (de) 1992-05-13
CA1341442C (en) 2003-10-07
ATE76102T1 (de) 1992-05-15
JPH0548093B2 (de) 1993-07-20
US4736866B1 (en) 1988-04-12
US4736866A (en) 1988-04-12

Similar Documents

Publication Publication Date Title
DE3586020D1 (de) Verfahren zur schaffung genetisch manipulierter tiere.
DD148464A3 (de) Verfahren zur gewinnung von l-threonin
DE3579756D1 (de) Einrichtung und verfahren zur wassertierzucht auf see.
DE58905979D1 (de) Verfahren zur aufzucht von wassertieren.
DE3380895D1 (de) Verfahren zur behandlung von eiern.
DE3169707D1 (de) Pet collars containing ectoparasiticides
DE3874028D1 (de) Verfahren zur justierung von photomasken.
DE3786148T2 (de) Verfahren zur hetero-epitaktischen zuechtung.
DE68906545D1 (de) Verfahren zum melken eines tieres.
AT373469B (de) Verfahren und vorrichtung zur aufzucht von wassertieren
DE3576580D1 (de) Verfahren zur behandlung farbphotographischer elemente.
ATA238280A (de) Verfahren zur herstellung von alkali- oder erdalkaliperoxiden
DE3380980D1 (de) Verfahren zum herstellen von pilzbrut.
DD152262A3 (de) Verfahren zur denitrierung von wasser
DE3684898D1 (de) Verfahren zur zuechtung von tierzellen.
AT363717B (de) Verfahren zur unkrautbekaempfung
DE3879931T2 (de) Verfahren zur werkstoffbestrahlung.
AT362167B (de) Verfahren zur pruefung nichtmagnetisierbarer schwerstangen
ATA408881A (de) Verfahren zur herstellung eines identifizierungsdokumentes
AT371800B (de) Verfahren zur herstellung von bromhexin
LU81078A1 (de) Verfahren zur herstellung eines tierfuttermittels
AT360942B (de) Verfahren zum zuechten von basidiomyceten
AT376686B (de) Verfahren zur stabilisierung von halogenierungs- mitteln
AT374338B (de) Verfahren und vorrichtung zur aufzucht von jungtieren
ATA335781A (de) Verfahren zur gewinnung von wasserunloeslichen getreidebestandteilen

Legal Events

Date Code Title Description
8363 Opposition against the patent